An artificial-intelligence-proposed ALS therapy delayed the onset of the disease in an animal model by promoting cellular resistance to oxidative stress.
The project is led by Dr. Richard Mead and Dr. Laura Ferraiuolo who expect to present their findings at the Motor Neurone Disease Association 28th International Symposium in Boston in December.
These finding are consistent with those observed in epidemiological and clinical case studies which suggest that neurotoxic chemicals that increase oxidative stress can hasten subclinical disease progression and unmask latent disease. Such therapeutics are not likely to significantly slow disease progression in the later stages but administration of such drugs to persons known to be at risk for developing ALS could delay onset sufficiently to be of clinical benefit.
Link to original article in ALS News Today
The project is led by Dr. Richard Mead and Dr. Laura Ferraiuolo who expect to present their findings at the Motor Neurone Disease Association 28th International Symposium in Boston in December.
These finding are consistent with those observed in epidemiological and clinical case studies which suggest that neurotoxic chemicals that increase oxidative stress can hasten subclinical disease progression and unmask latent disease. Such therapeutics are not likely to significantly slow disease progression in the later stages but administration of such drugs to persons known to be at risk for developing ALS could delay onset sufficiently to be of clinical benefit.
Link to original article in ALS News Today
RSS Feed
